tailieunhanh - Báo cáo y học: "Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab"

Tuyển tập các báo cáo nghiên cứu về y học được đăng trên tạp chí y học General Psychiatry cung cấp cho các bạn kiến thức về ngành y đề tài: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. | Available online http content 7 3 R439 Research article Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab Xenofon Baraliakos1 Joachim Listing2 Jan Brandt1 Martin Rudwaleit3 Joachim Sieper3 and Juergen Braun1 1Rheumazentrum Ruhrgebiet Herne Germany 2German Rheumatism Research Center Berlin Germany 3Charité Medical University of Berlin Campus Benjamin Franklin Department of Rheumatology Germany Corresponding author Juergen Braun Received 30 Nov 2004 Revisions requested 22 Dec 2004 Revisions received 7 Jan 2005 Accepted 17 Jan 2005 Published 21 Feb 2005 Arthritis Research Therapy 2005 7 R439-R444 DOI 86 ar1693 2005 Baraliakos et al. licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is cited. Open Access Abstract We analyzed the clinical response and the time to relapse after discontinuation of continuous long-term infliximab therapy in patients with ankylosing spondylitis AS . After 3 years of infliximab therapy all AS patients n 42 discontinued treatment time point TP 1 and were visited regularly for 1 year in order to assess the time to relapse TP2 . Relapse was defined as an increase to a value 4 on the Bath Ankylosing Spondylitis Disease Activity Index BASDAI and a physician s global assessment 4 according to the recommendations of the Assessments in Ankylosing Spondylitis ASAS working group. After 52 weeks 41 of the 42 patients had to be reinfused because of relapse. The mean change in the BASDAI between TP1 and TP2 was and that in the physician s global assessment was both P . The mean time to relapse was weeks weeks range 7 to 45 . Ten .